Canada Markets closed

COMPASS Pathways plc (CMPS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.26-0.71 (-7.92%)
At close: 04:00PM EDT
8.54 +0.28 (+3.39%)
After hours: 05:07PM EDT
Sign in to post a message.
  • R
    Roger
    CMPS is heating up its engine. . .
  • R
    Roger
    It's good to see investors noticing CMPS' good ER and update. Reduced operating costs, $243M cash and on pace to start Phase III later this year. . . My question is: if CMPS has a cash runway of 2 years, why did they open the door to an ATM? Is this just to give them the option if needed? Or are they planning on expanding into trials of anorexia and autism and would need more cash? It seems like bad timing with SP down a lot, yet in the long run could be a positive.
  • D
    DB
    dilution incoming...hoping the added liquidity helps us fight the shorts. https://ir.compasspathways.com/static-files/5d772372-7c45-48f2-b620-e7b69790c729
  • R
    Roger
    CMPS is now trading at book value
  • K
    Ko
    Imagine buying at $57
  • B
    Bryn
    There’s something going on here that’s for sure. This legal challenge against the patent seems to be the driving force. I’m not an expert on patents but logically what Compass is doing is taking psylocibin which it’s not possible to take in measured form in its natural state. Compass has not only found a way to make every dose measurable and exactly the same but has tested this dose in a clinical setting. That’s a huge amount of work and research. If the FDA approves the results and gives the green light it is separate to the patent. They’re not judging the validity of the patent, rather it’s efficacy. Which seems promising. The legal action is therefore putting pressure on the foundations of Compass business model which knocks on to its share price (value). Even with FDA approval this legal challenge hangs around, right. However what bugs me is why challenge a drug which has been formulated in such a way that it can be regulated and brought to market to help a lot of people? It’s not as though Compass are trying to take ownership of psylocibin as people can grow it if they want and have done for a long time. So the basis for the legal attack seems suspect to me. It doesn’t stack up. So the question has to be asked as to whether those taking legal action are funding and monetising their attack though short selling. If that’s the case sooner or later there will be a short squeeze as there isn’t much money to be made short selling anymore with the share price where it is (low). Just a hunch but this company isn’t about to go bust (as one comment mentions) and has a runway of cash to take it through FDA approval if it’s thats possible. It’s not revenue generating - of course it isn’t, it’s not got FDA approval so that’s not the problem either. The big question here is whether legal action is an Elliot style hostile money making scheme. Elliot will go after underperforming established businesses rather than pre-revenue. So question is what’s going on here and only logical answer in my mind is that the legal action is not ‘for the greater good’ as it claims to be but rather a mechanism to make hostile shorting of the stock highly lucrative at shareholders expense (in the short term at least). I will hang on to see what the FDA says and if it’s good news price could rebound and squeeze out the shorts which compounds the rebound. Think Tesla.
  • J
    Joe
    When does the death of compass stop
  • D
    DEREK
    you can thank me I just bought in recently and already I'm a bag holder sorry 😞
  • O
    Omar
    They guided to having an FDA meeting in April to discuss the COMP360 Phase III trial—no news on this?
  • G
    G Ram
    Hello fellow bagholders!
  • M
    Mohammad
    FDA approval for stage three trials should be announced this month per a press release from back in November (it’s a rough estimate from CMPS itself), if it should come trough I would expect a relatively large pop back to the $20-25 range.
  • S
    Sweet
    what do WMT and TGT do to CMPS? very strange
  • D
    DB
    short sale restriction has kicked in - not sure what this is all about - positive news from Oregon today and still a sectoral rout on an overall green day.
  • R
    Roger
    Solid ER this morning. They beat EPS and have lots of cash
  • Y
    Yahoo Finance Insights
    COMPASS Pathways reached a 52 Week low at 10.05
  • L
    LAWRENCE
    Bankruptcy coming -- cash flow negative -- running low on money --
  • R
    Roger
    CMPS is potentially trend-reversing. For the second time in two weeks it has pierced the upper Bollinger Bar and 50 DMA. And for the past two weeks, the 10/20 DMAs have served as support.
  • S
    Scarry
    Why is this stock rallying so much??
  • Y
    Yahoo Finance Insights
    COMPASS Pathways reached an all time low at 9.61
  • S
    Scarry
    DON’T RALLY !!!!!!